We appreciate the insightful remarks of Dr Spaide and of Dr Geier and colleagues regarding the use of the ganciclovir-containing intraocular device for the control of progressive CMV retinitis. The issue that both of these letters raise is exceedingly important regarding survival of patients with AIDS-associated CMV retinitis.Our report presented the results of an initial pilot study regarding the safety and efficacy of a ganciclovircontaining device that would deliver the drug intraocularly over a long period of time.1 We would like to emphasize that the study was not designed to evaluate the effect on patients' survival. We recruited patients who had active, progressive CMV retinitis in one or both eyes. Patients with symptomatic, systemic CMV infection or visual acuity of less than 20/200 due to macular scarring or optic nerve involvement were excluded. Our only end point was the determination of the effect of the slow
Anand R, Nightingale SD, Fish RH, Smith TJ, Ashton P. Ganciclovir Intraocular Device and Patient Survival-Reply. Arch Ophthalmol. 1994;112(1):20–21. doi:10.1001/archopht.1994.01090130029006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: